Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized observer-blinded dose-response trial of VLA1553 in healthy children aged 1 to 11 years
2026-000022-41Phase 2
- Sponsor
- Valneva
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of chikungunya vaccine (live) in Chikungunya (CHIKV) (2 arms), sponsored by Valneva. Primary endpoint: Tolerability.
02
Drugs
chikungunya vaccine (live)
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on 2026-000022-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000022-41.